Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hoyle

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
The Journal of Antimicrobial Chemotherapy|February 22, 2005
Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175)Keith Miller, Christopher Storey, William J Stubbings, et al.
Health Technology Assessment (Winchester, England)|December 24, 2009
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluationJ Thompson Coon, M Hoyle, C Green, et al.
Health Technology Assessment (Winchester, England)|May 4, 2012
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluationG Rogers, M Hoyle, J Thompson Coon, et al.
Practical Radiation Oncology|March 29, 2014
Subjective and objective quantification of physician's workload and performance during radiation therapy planning tasksLukasz M Mazur, Prithima R Mosaly, Lesley M Hoyle, et al.
British Journal of Cancer|September 19, 2013
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancerF Joulain, I Proskorovsky, C Allegra, et al.
Health Technology Assessment (Winchester, England)|April 4, 2013
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic modelM Hoyle, L Crathorne, J Peters, et al.
Journal of Vascular Surgery|September 1, 1994
Case management in cerebral revascularizationR M Hoyle, J M Jenkins, W H Edwards, et al.
British Journal of Cancer|July 2, 2009
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectivenessJ S Thompson Coon, Z Liu, M Hoyle, et al.
Practical Radiation Oncology|June 4, 2014
Relating physician's workload with errors during radiation therapy planningLukasz M Mazur, Prithima R Mosaly, Lesley M Hoyle, et al.
Plos One|February 10, 2023
Agricultural margins could enhance landscape connectivity for pollinating insects across the Central Valley of California, U.S.AThomas E Dilts, Scott H Black, Sarah M Hoyle, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
The Journal of Antimicrobial Chemotherapy|February 22, 2005
Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175)Keith Miller, Christopher Storey, William J Stubbings, et al.
Health Technology Assessment (Winchester, England)|December 24, 2009
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluationJ Thompson Coon, M Hoyle, C Green, et al.
Health Technology Assessment (Winchester, England)|May 4, 2012
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluationG Rogers, M Hoyle, J Thompson Coon, et al.
Practical Radiation Oncology|March 29, 2014
Subjective and objective quantification of physician's workload and performance during radiation therapy planning tasksLukasz M Mazur, Prithima R Mosaly, Lesley M Hoyle, et al.
British Journal of Cancer|September 19, 2013
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancerF Joulain, I Proskorovsky, C Allegra, et al.
Health Technology Assessment (Winchester, England)|April 4, 2013
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic modelM Hoyle, L Crathorne, J Peters, et al.
Journal of Vascular Surgery|September 1, 1994
Case management in cerebral revascularizationR M Hoyle, J M Jenkins, W H Edwards, et al.
British Journal of Cancer|July 2, 2009
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectivenessJ S Thompson Coon, Z Liu, M Hoyle, et al.
Practical Radiation Oncology|June 4, 2014
Relating physician's workload with errors during radiation therapy planningLukasz M Mazur, Prithima R Mosaly, Lesley M Hoyle, et al.
Plos One|February 10, 2023
Agricultural margins could enhance landscape connectivity for pollinating insects across the Central Valley of California, U.S.AThomas E Dilts, Scott H Black, Sarah M Hoyle, et al.
Pageof 6